Premium
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
Author(s) -
Landgren Ola,
Weisel Katja,
Rosinol Laura,
Touzeau Cyrille,
Turgut Mehmet,
Hajek Roman,
Mollee Peter,
Kim Jin Seok,
Shu Natalie,
Hu Xuguang,
Li Chuang,
Usmani Saad Z.
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18233
Subject(s) - carfilzomib , daratumumab , medicine , subgroup analysis , oncology , hazard ratio , multiple myeloma , refractory (planetary science) , dexamethasone , lenalidomide , confidence interval , physics , astrobiology
CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high‐risk and 87% versus 79% in standard‐risk groups. Median progression‐free survival was 11.2 versus 7.4 months in high‐risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard‐risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high‐risk cytogenetics.